GlassScriptPhysician profile
Atif Hussain
NPI 1417905431
$4,512.37
in general payments reported to CMS, 2019-2025
30 companies · $985 in 2025
The $985 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $393 · 2021: $333 · 2022: $458 · 2023: $588 · 2024: $773 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,299 · Travel and Lodging: $47.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,298.53 |
| Travel and Lodging | $47.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $794.52 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $614.25 | 2019-2025 | |
| Amgen INC. | $464.55 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $337.23 | 2019-2025 | |
| Medtronic, INC. | $309.61 | 2024-2025 | Corevalve Evolut R |
| Amarin Pharma, INC. | $242.86 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $242.01 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $221.32 | 2021-2025 | Verquvo, Keytruda |
| Astrazeneca Pharmaceuticals LP | $214.15 | 2019-2023 | Andexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.13 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $131.34 | 2020-2025 | Lifevest |
| Astellas Pharma US INC | $114.95 | 2019-2021 | |
| Edwards Lifesciences Corporation | $98.16 | 2019-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Regeneron Healthcare Solutions, INC. | $70.28 | 2019 | |
| Heartflow, INC. | $46.31 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $44.82 | 2022 | |
| Inspire Medical Systems, INC. | $44.51 | 2024 | Inspire |
| Bard Peripheral Vascular, INC. | $43.29 | 2023 | Venovo |
| Irhythm Technologies, INC. | $42.24 | 2021-2024 | Zio Monitor, Zio Xt Patch |
| Kiniksa Pharmaceuticals International, Plc | $41.87 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $41.83 | 2025 | Amvuttra |
| Abbott Laboratories | $32.55 | 2019-2025 | Cardiomems |
| Terumo Medical Corporation | $27.38 | 2023 | Heartrail, Glidewire |
| Abiomed | $26.75 | 2019 | |
| Esperion Therapeutics, INC. | $23.68 | 2021 | |
| Boston Scientific Corporation | $22.49 | 2024 | Watchman Flx |
| Medtronic Vascular, INC. | $18.00 | 2020 | |
| Lundbeck LLC | $17.68 | 2020 | |
| Sanofi-Aventis U.S. LLC | $16.32 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $16.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atif Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.